NCT00259818已完成1 期
An Open-Label Phase I Dose Escalation Study of Intravenous Infusion of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Refractory Malignant Tumors
Erimos Pharmaceuticals4 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2005年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 4
- 主要终点
- Safety
研究概览
简要总结
This is a Phase I, dose escalation study of EM-1421 administered by intravenous infusion (IV) for five consecutive days every 28 days to patients with solid tumors refractory to current therapies. There have been no previous human studies of intravenous (into one's vein) EM-1421 treatment; however, lab research (research in test tubes and/or animals) suggests that EM-1421 has shown some activity against tumors in animals. This activity in animal models suggests that EM-1421 may be a useful chemotherapy for human cancer.
The primary objective of this study is to determine the safety and maximum tolerated dose of EM-1421 given by intravenous infusion. The efficacy of the treatment will also be measured.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects ≥ 18 years of age.
- •Subjects with documented evidence of cancer with clinically evaluable disease. Cancer can be recurrent after primary treatment with surgery, radiation therapy, and/or chemotherapy and may include those patients for whom no standard or curative therapy exists.
- •Measurable tumor by imaging (computed tomography [CT] per Response Evaluation Criteria in Solid Tumors [RECIST] criteria).
- •Life expectancy of at least 3 months in the Investigator's opinion.
- •Negative pregnancy test, if in women of childbearing potential, within one week of starting therapy.
- •Subjects who have provided written informed consent to participate in the study.
- •ECOG performance status of 0, 1, or
- •Absolute neutrophil ≥ 1500 cells/µL, hemoglobin ≥ 9 gm/dl, platelets ≥ 100,000/µL, ALT/AST ≤ 3 x ULN (upper limit of the normal range) unless involved with tumor then < 5 x ULN, bilirubin ≤ 1.5 x ULN, and creatinine ≤ 1.5 x ULN.
排除标准
- •Women who are pregnant or breast-feeding (women of child-bearing potential must have a negative serum pregnancy test within one week of entering the study.)
- •Women of child-bearing potential who are unwilling to use two medically acceptable forms of contraception during the course of the study (surgical sterilization, approved hormonal contraceptives, or barrier method with spermicide).
- •Treatment with a prior investigational agent within 28 days of entering the study.
- •Subjects unable to comply with the study requirements.
- •Subjects with a known sensitivity to any of the study medication components.
- •Prior chemotherapy, radiation therapy, or surgery for the primary tumor within 28 days of dosing and/or has not recovered from prior therapy toxicities - with the exception of non-experimental chronic hormone therapy for currently progressive metastatic prostate cancer. However, local radiation to a site of symptomatic disease will be acceptable if it has been completed at least 14 days prior to study drug initiation and subjects have recovered from all treatment-related side effects.
- •Subjects exhibiting any of the following: a marked baseline prolongation of QT/QTc interval (repeated demonstration of a calculated QTc interval > 450), a history of additional risk factors for torsades de pointes (TdP) (e.g., heart failure, hypokalemia, family history of long QT syndrome), and subjects unable or unwilling to refrain from using medications that are known to prolong the QT/QTc ratio during the course of the study.
结局指标
主要结局
Safety
Maximum tolerated dose
次要结局
- Pharmacokinetic parameters
- Pharmacodynamic parameters
- Anti-tumor activity of regimen
- Feasibility of regimen
研究者
研究点 (4)
Loading locations...
相似试验
已完成
早期 1 期
The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's DiseaseHuntington DiseaseNCT06024265ExoRNA Bioscience10
已完成
1 期
A Study of IMP4297 in Patients With Advanced Solid TumorsAdvanced Solid TumoursBreast CancerOvarian CancerProstate CancerNCT03508011Impact Therapeutics, Inc.57
已完成
1 期
Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung CancerCarcinoma, Non-Small-Cell LungNCT02211833Boehringer Ingelheim41
已完成
1 期
A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04338724CStone Pharmaceuticals6
招募中
1 期
A Study of KC1036 in Patients with Advanced Solid TumorsAdvanced Solid TumorsNCT04387916Beijing Konruns Pharmaceutical Co., Ltd.207